Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients.

Compr Psychiatry

Geriatric Research Education and Clinical Center, VA Northeast Ohio Healthcare System, 10701 East Blvd, Cleveland, OH 44106, United States; Frances Payne Bolton School of Nursing, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, United States.

Published: November 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.comppsych.2021.152269DOI Listing

Publication Analysis

Top Keywords

effectiveness paliperidone
4
paliperidone palmitate
4
palmitate one-month
4
one-month long-acting
4
long-acting injection
4
injection obese
4
obese non-obese
4
non-obese patients
4
effectiveness
1
palmitate
1

Similar Publications

Introduction: Daily oral antipsychotics (OAPs) are the mainstay of schizophrenia treatment; however, long-acting injectable antipsychotics (LAIs) are associated with better treatment adherence and improved outcomes.

Methods: This study assessed the real-world comparative effectiveness of LAIs and daily OAPs using claims data from a nationally representative sample of fee-for-service Medicare beneficiaries with schizophrenia. Antipsychotic discontinuation, psychiatric hospitalization, and treatment failure were compared relative to different reference groups using within-individual Cox regression models.

View Article and Find Full Text PDF

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

View Article and Find Full Text PDF

Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder.

J Child Adolesc Psychopharmacol

January 2025

Director of Co-Founder and Founder of Schizophrenia Society, University of Cincinnati, Cincinnati, Ohio, USA.

Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions.

View Article and Find Full Text PDF

Background: This scoping review focuses on the occurrence of tachyphylaxis, defined as reduced responsiveness upon reinitiating a previously effective medication. This phenomenon is previously documented in antidepressants and mood stabilizers.

Aim: To explore the frequency, treatment strategies, and predictability of tachyphylaxis across all psychotropic medications.

View Article and Find Full Text PDF

Introduction: The benefits of long-acting injectable antipsychotics have been documented in several observational studies, but data remain scarce in Latin America. This study aimed at evaluating the effectiveness of paliperidone palmitate once monthly (PP1M) on treatment adherence and relapse in the schizophrenia population followed in a government-funded mental health care facility in Colombia.

Methods: A mirror-image study was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!